11/7
09:51 am
sabs
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
High
Report
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
11/7
09:10 am
sabs
Rating for SABS
High
Report
Rating for SABS
10/9
08:33 am
sabs
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.
Medium
Report
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.
10/9
08:33 am
sabs
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.
Medium
Report
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.
10/9
08:27 am
sabs
Rating for SABS
Medium
Report
Rating for SABS
10/9
08:27 am
sabs
Rating for SABS
Medium
Report
Rating for SABS
10/9
07:22 am
sabs
SAB Biotherapeutics initiated with bullish view at Craig-Hallum
Low
Report
SAB Biotherapeutics initiated with bullish view at Craig-Hallum
10/9
07:22 am
sabs
SAB Biotherapeutics initiated with bullish view at Craig-Hallum
Low
Report
SAB Biotherapeutics initiated with bullish view at Craig-Hallum